These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Karakonstantis S; Kritsotakis EI; Gikas A Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545 [TBL] [Abstract][Full Text] [Related]
4. Resistance to polymyxins in Gram-negative organisms. Jeannot K; Bolard A; Plésiat P Int J Antimicrob Agents; 2017 May; 49(5):526-535. PubMed ID: 28163137 [TBL] [Abstract][Full Text] [Related]
5. Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes. Almangour TA; Garcia E; Zhou Q; Forrest A; Kaye KS; Li J; Velkov T; Rao GG Int J Antimicrob Agents; 2021 Jun; 57(6):106328. PubMed ID: 33785362 [TBL] [Abstract][Full Text] [Related]
6. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Vidaillac C; Benichou L; Duval RE Antimicrob Agents Chemother; 2012 Sep; 56(9):4856-61. PubMed ID: 22751540 [TBL] [Abstract][Full Text] [Related]
7. Performances of the Rapid Polymyxin Lescat M; Poirel L; Jayol A; Nordmann P Microb Drug Resist; 2019 May; 25(4):520-523. PubMed ID: 30508392 [No Abstract] [Full Text] [Related]
8. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562 [TBL] [Abstract][Full Text] [Related]
9. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria. Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates. Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217 [TBL] [Abstract][Full Text] [Related]
11. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria. Doymaz MZ; Karaaslan E Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061 [No Abstract] [Full Text] [Related]
12. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend. Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418 [TBL] [Abstract][Full Text] [Related]
13. Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates. Choi MJ; Ko KS J Antimicrob Chemother; 2014 Jan; 69(1):275-7. PubMed ID: 23997018 [No Abstract] [Full Text] [Related]
14. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Falagas ME; Bliziotis IA Int J Antimicrob Agents; 2007 Jun; 29(6):630-6. PubMed ID: 17306965 [TBL] [Abstract][Full Text] [Related]
15. Emergence of multiple carbapenemase-producing Gram-negative species, colistin-resistant KPC-2-producing Klebsiella pneumoniae ST11, IMP-7-producing Pseudomonas aeruginosa ST357, and OXA-23-producing Acinetobacter baumannii ST1050, in a single patient. Nishida S; Ishigaki S; Asahara M; Furukawa T; Ono Y Int J Antimicrob Agents; 2018 Oct; 52(4):512-514. PubMed ID: 30318057 [No Abstract] [Full Text] [Related]
16. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs. Mezzatesta ML; Caio C; Gona F; Cormaci R; Salerno I; Zingali T; Denaro C; Gennaro M; Quattrone C; Stefani S Int J Antimicrob Agents; 2014 Aug; 44(2):112-6. PubMed ID: 25059444 [TBL] [Abstract][Full Text] [Related]
17. Intravenous colistin administration in neonates. Jajoo M; Kumar V; Jain M; Kumari S; Manchanda V Pediatr Infect Dis J; 2011 Mar; 30(3):218-21. PubMed ID: 21245777 [TBL] [Abstract][Full Text] [Related]
18. Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates. Choi MJ; Park YK; Peck KR; Ko KS Int J Antimicrob Agents; 2014 Nov; 44(5):475-6. PubMed ID: 25443890 [No Abstract] [Full Text] [Related]
19. Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for 'Old' Polymyxins. Paterson DL; Bonomo RA Adv Exp Med Biol; 2019; 1145():9-13. PubMed ID: 31364068 [TBL] [Abstract][Full Text] [Related]
20. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. Landman D; Bratu S; Kochar S; Panwar M; Trehan M; Doymaz M; Quale J J Antimicrob Chemother; 2007 Jul; 60(1):78-82. PubMed ID: 17490999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]